ZA200810166B - Phenylephrine pharmaceutical formulations and compositions for colonic absorption - Google Patents

Phenylephrine pharmaceutical formulations and compositions for colonic absorption

Info

Publication number
ZA200810166B
ZA200810166B ZA200810166A ZA200810166A ZA200810166B ZA 200810166 B ZA200810166 B ZA 200810166B ZA 200810166 A ZA200810166 A ZA 200810166A ZA 200810166 A ZA200810166 A ZA 200810166A ZA 200810166 B ZA200810166 B ZA 200810166B
Authority
ZA
South Africa
Prior art keywords
compositions
pharmaceutical formulations
colonic absorption
phenylephrine
phenylephrine pharmaceutical
Prior art date
Application number
ZA200810166A
Other languages
English (en)
Inventor
Monteith David
O'mullane John
Joseph P Reo
Robert T Nowak
Wan Jiansheng
Mohammed A Kabir
Malaz A Abutarif
Glenn E Fritz
Original Assignee
Schering Plough Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Healthcare filed Critical Schering Plough Healthcare
Publication of ZA200810166B publication Critical patent/ZA200810166B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200810166A 2006-06-01 2008-11-28 Phenylephrine pharmaceutical formulations and compositions for colonic absorption ZA200810166B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81002106P 2006-06-01 2006-06-01

Publications (1)

Publication Number Publication Date
ZA200810166B true ZA200810166B (en) 2009-08-26

Family

ID=38659327

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200810164A ZA200810164B (en) 2006-06-01 2008-11-28 Sustained release pharmaceutical dosage form containing phenylphrine
ZA200810166A ZA200810166B (en) 2006-06-01 2008-11-28 Phenylephrine pharmaceutical formulations and compositions for colonic absorption

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200810164A ZA200810164B (en) 2006-06-01 2008-11-28 Sustained release pharmaceutical dosage form containing phenylphrine

Country Status (15)

Country Link
US (1) US20100068280A1 (xx)
EP (2) EP2253310A1 (xx)
JP (1) JP2009538918A (xx)
KR (1) KR20090018979A (xx)
CN (2) CN101495099A (xx)
AU (1) AU2007254818A1 (xx)
BR (1) BRPI0711718A2 (xx)
CA (1) CA2653936A1 (xx)
MX (1) MX2008015359A (xx)
NO (1) NO20085415L (xx)
NZ (1) NZ573174A (xx)
RU (1) RU2008151950A (xx)
SG (1) SG175619A1 (xx)
WO (1) WO2007143155A2 (xx)
ZA (2) ZA200810164B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612196T3 (es) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
MX2009001925A (es) * 2009-02-20 2010-08-20 Senosiain S A De C V Lab Composicion farmaceutica oral para uso en enfermedades respiratorias.
KR102354472B1 (ko) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
JP5876146B2 (ja) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
HUE055894T2 (hu) 2012-11-15 2021-12-28 Incyte Holdings Corp A ruxolitinib nyújtott felszabadulású dózisformái
DK2953617T3 (da) * 2013-02-06 2020-01-20 Hermes Arzneimittel Gmbh Farmaceutiske sammensætninger, der inkorporerer lavdosislægemidler
US20140271891A1 (en) 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles and use thereof in pharmaceutical formulations
US20140271893A1 (en) 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US20160303077A1 (en) * 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
US20170216213A1 (en) * 2014-07-30 2017-08-03 Merck Patent Gmbh Directly compressible polyvinyl alcohols
ES2811120T3 (es) * 2014-07-30 2021-03-10 Merck Patent Gmbh Tipos de poli (alcohol vinílico) en forma de polvo, que pueden comprimirse directamente
US20170209380A1 (en) * 2014-07-30 2017-07-27 Merck Patent Gmbh Directly compressible composition comprising microcrystalline cellulose
BR112017005574A2 (pt) 2014-09-19 2017-12-12 Procter & Gamble formas de dosagem de liberação pulsada de fenilefrina
JP6078514B2 (ja) * 2014-10-30 2017-02-08 コリア ユナイテッド ファーム，インク 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠
MA41152A (fr) 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
US20190192444A1 (en) * 2016-03-30 2019-06-27 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022023463A1 (en) * 2020-07-30 2022-02-03 Faes Farma, S.A. Decongestant drug delivery system
CN115400128B (zh) * 2022-04-27 2024-01-23 则正(上海)生物科技有限公司 含盐酸去氧肾上腺素片剂、制备方法及应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (xx) 1963-04-24
US3419565A (en) 1963-04-24 1968-12-31 Schering Corp Aza-dibenzocycloheptenes
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US3696188A (en) * 1971-06-16 1972-10-03 Schering Corp Laminated tablets
US3878217A (en) 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
NO155805C (no) 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
ATE118345T1 (de) * 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
NL1005394C1 (nl) * 1996-04-01 1997-10-02 Kokbing Lo Bevestigingselement en band bevestigd met bevestigingselement.
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
CA2268546A1 (en) * 1996-10-31 1998-05-07 Schering Corporation Composition, for the treatment of asthma, containing loratadine and a decongestant
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
MX9701946A (es) * 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
IN186245B (xx) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045676A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030083354A1 (en) * 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20030114535A1 (en) * 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
US20030203027A1 (en) * 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
JP4473539B2 (ja) 2003-08-12 2010-06-02 エスエス製薬株式会社 医薬組成物
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
CN101262852A (zh) * 2004-12-13 2008-09-10 麦克内尔-Ppc股份有限公司 稳定活性药物成分的组合物和方法
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) * 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US7378082B1 (en) * 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects

Also Published As

Publication number Publication date
SG175619A1 (en) 2011-11-28
WO2007143155A2 (en) 2007-12-13
EP2020994A2 (en) 2009-02-11
JP2009538918A (ja) 2009-11-12
CA2653936A1 (en) 2007-12-13
NO20085415L (no) 2008-12-30
ZA200810164B (en) 2009-11-25
CN101495100A (zh) 2009-07-29
BRPI0711718A2 (pt) 2011-11-29
KR20090018979A (ko) 2009-02-24
MX2008015359A (es) 2009-03-06
EP2253310A1 (en) 2010-11-24
CN101495100B (zh) 2014-09-17
CN101495099A (zh) 2009-07-29
AU2007254818A1 (en) 2007-12-13
NZ573174A (en) 2012-01-12
RU2008151950A (ru) 2010-07-20
US20100068280A1 (en) 2010-03-18
WO2007143155A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
ZA200810166B (en) Phenylephrine pharmaceutical formulations and compositions for colonic absorption
SI3984528T1 (sl) Farmacevtski sestavki, ki vsebujejo nilotinib
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0625322D0 (en) Pharmaceutical compositions
IL193894A0 (en) Pharmaceutical compositions containing luliconazole for external use
ZA200808530B (en) Pharmaceutical composition for external use
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL220800A (en) Stabilized Pharmaceutical Preparations Containing Passoterodine
ZA201004654B (en) Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption
HK1138732A1 (en) Pharmaceutical compositions
EP2057987A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ENCAPSULATED STATINE NANOPARTICLE
GB0617191D0 (en) Improvements in pharmaceutical compositions
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
GB0614586D0 (en) Pharmaceutical Formulation
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
IL198160A0 (en) Pharmaceutical formulations
SI1886686T1 (sl) Farmacevtski sestavek, ki vsebuje mometazon furoat
GB0612556D0 (en) Topical pharmaceutical formulations
GB0615461D0 (en) Pharmaceutical formulations
IL178378A0 (en) Extended release pharmaceutical compositions
HU0600939D0 (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions